Birth defects a concern, but cardio may dominate Qnexa's 2nd FDA panel
This article was originally published in Scrip
Executive Summary
Investors did not lose heart on 17 February in hopes that Vivus still has a chance to obtain US approval of its experimental combination weight-loss pill Qnexa (phentermine/topiramate), despite concerns again raised by the US FDA over the potential of birth defects and adverse cardiovascular effects linked with the product in clinical testing.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.